SCHEMBL2032136

SCHEMBL2032136

CCN(C(=O)CCl)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.66
RAB9A P51151 4/20 0.66
PAX8 Q06710 3/20 0.66
JAK2 O60674 2/20 0.66
ALDH1A1 P00352 6/20 0.66
HTT P42858 5/20 0.66
GLA P06280 2/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
TSHR P16473 1/20 0.66
KMT2A Q03164 5/20 0.60
POLB P06746 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
TP53 P04637 3/20 0.56
LMNA P02545 2/20 0.56
MEN1 O00255 3/20 0.54
RNF4 P78317 1/20 0.49
MITF O75030 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4160577 0.85 RAB9A (0.77) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL29522704 0.84 NPC1 (0.57) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL8181665 0.84 ALDH1A1 (0.70) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL2030599 0.84 ALDH1A1 (0.70) ALDH1A1HTTGLATSHRKMT2A
SCHEMBL9492831 0.82 ALDH1A1 (0.68) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL3837959 0.82 ALDH1A1 (0.68) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL8759407 0.82 NPC1 (0.59) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL6545547 0.82 NPC1 (0.88) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL8439833 0.81 NPC1 (0.46) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL18338240 0.81 ALDH1A1 (0.70) NPC1RAB9APAX8JAK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1212056-B1 METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES US GOV HEALTH & HUMAN SERV (US) 2005-12-07 EP claimed
EP-1212056-A1 METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2002-06-12 EP claimed
US-20020002144-A1 Methods and compositions for bisubstrate inhibitors of acetyltransferases THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2002-01-03 US claimed
WO-2001012185-A1 METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2001-02-22 WO claimed
EP-0786483-B1 Process for an activated anionic lactam polymerisation INVENTA AG (CH) 2000-04-19 EP claimed
US-5756647-A LIQUID SYSTEM: CATALYST, ACTIVATOR AND SOLVENT EMS-INVENTA AG (CH) 1998-05-26 US claimed
EP-0786483-A2 Process for an activated anionic lactam polymerisation EMS-INVENTA AG (CH) 1997-07-30 EP claimed
US-20200207989-A1 FLUORESCENT PROBE FOR ALDH3A1 DETECTION THE UNIVERSITY OF TOKYO (JP) 2020-07-02 US disclosed
US-7964593-B2 Indolone-acetamide derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2011-06-21 US disclosed
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2010-03-18 US disclosed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US disclosed
EP-1036794-A1 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF Dainippon Pharmaceutical Co., Ltd. (JP) 2000-09-20 EP disclosed
EP-0786482-B1 Liquid system for the anionic lactam polymerisation INVENTA AG (CH) 2000-08-16 EP disclosed
US-5760164-A STORAGE STABILITY EMS-INVENTA AG (CH) 1998-06-02 US disclosed
EP-0786482-A2 Liquid system for the anionic lactam polymerisation EMS-INVENTA AG (CH) 1997-07-30 EP disclosed
US-4212764-A Quaternary polyvinyl heterocyclic compositions and use as corrosion inhibitors PETROLITE CORPORATION (US) 1980-07-15 US disclosed
US-4099954-A Amide phosphorothiolate herbicides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1978-07-11 US disclosed
US-3972928-A Regulating plant growth with quaternary phosphonium aliphatic carboxamide salts BAYCHEM CORPORATION (US) 1976-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD NPC1 4017/4885RAB9A 287/4885PAX8 2728/4885
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses AANAT, TPH2, CYP1A2 NPC1 2588/4885RAB9A 2369/4885PAX8 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.